Le Lézard10d
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
Results demonstrated statistically significant effects on biomarkers that predict ALS disease progression and severity Evidence of brain penetration, target engagement, and potential anti-seizure ...
pharmaphorum1d
4th ALS Drug Development Summit
The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...
Le Lézard10d
Accenture and CrowdStrike Team to Transform Security Operations, Mitigating Cyber Threats and Reducing Costs with AI-native Solutions
Accenture and CrowdStrike are collaborating to drive cybersecurity transformation, helping clients confidently navigate the next wave of innovation and growth. By combining Accenture's security ...
National Rugby League14d
International Women's Day: Paying tribute to HOF trailblazers
“I love the fact the attitudes have changed, not only from the fans watching the game, but to the administrators behind the scenes in the NRL, QRL and NSWRL who now support the women’s game ...
Five Strategies To Maximize ROI Of Corporate Social Impact Initiatives
Drawing from insights helping clients increase engagement, here are five key strategies to enhance the ROI of your corporate ...
Pharmabiz9d
QurAlis announces positive data from phase 1 trial of QRL-101 evaluating biomarkers of ALS and epilepsy in healthy volunteers
The decrease in SDTC observed with QRL-101 in this study was approximately 50% greater than previously reported for the Kv7 potassium channel opener ezogabine in a single-dose study in people with ALS ...